Table 4.

Adjusted Sputum Culture Conversion Rates and Treatment Outcomes Among Patients With Multidrug-resistant Tuberculosis Receiving a Bedaquiline- or Delamanid-Based Treatment Regimen

Outcome	Delamanid (95% CI)	Bedaquiline (95% CI)	P Value	E Value
SCC at 2 months, n = 91	.47 (.27–.68)	.67 (.56–.78)	.10	1.23
SCC at 6 months, n = 91	.74 (.60–.88)	.95 (.89–1.00)	<.01	1.56
Favorable outcomes, n = 84	.72 (.61–.82)	.96 (.91–1.00)	<.01	1.98

Variables adjusted for in all analyses included age, body mass index, gender, history of imprisonment, tobacco and alcohol use, diabetes mellitus, hepatitis C, human immunodeficiency virus infection, new versus prior treatment case, sputum smear status, cavitary disease, and number of effective drugs.

Abbreviations: CI, confidence interval; SCC, sputum culture conversion.